Kosuke Fujino
Overview
Explore the profile of Kosuke Fujino including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
374
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Takamori S, Endo M, Hamada A, Ohara S, Fukuda S, Tomioka Y, et al.
Clin Lung Cancer
. 2025 Jan;
PMID: 39824660
Background: While Epidermal growth factor receptor (EGFR) mutation-positive lung adenocarcinoma (LUAD) has favorable outcomes with targeted therapy, early-stage prognosis remains influenced by pathological factors and central nervous system (CNS) recurrence....
2.
Nomura K, Takada K, Kinoshita F, Muto S, Matsubara T, Kouki Y, et al.
Int J Cancer
. 2024 Nov;
156(7):1480-1491.
PMID: 39569608
The expression of programmed cell death-ligand 1 (PD-L1) and mutation in epidermal growth factor receptor (EGFR) are biomarkers used for perioperative treatment of lung adenocarcinoma. However, the clinical significance of...
3.
Matsushima R, Fujino K, Motooka Y, Yamada H, Shirakami C, Shinchi Y, et al.
Thorac Cancer
. 2024 Sep;
15(30):2166-2174.
PMID: 39250336
Background: Patients with early-stage lung cancer and interstitial lung disease have a poorer prognosis than those without interstitial lung disease. This study aimed to compare the long-term outcomes of lobar...
4.
Okabayashi H, Nakashima S, Fujino K, Imai M, Hamada S, Masunaga A, et al.
Intern Med
. 2024 Apr;
63(23):3221-3226.
PMID: 38569903
Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (DM)-associated interstitial lung disease (ILD) can sometimes be complicated by pneumomediastinum, although tension pneumomediastinum is extremely rare. We herein report a case of...
5.
Anai M, Saruwatari K, Imamura K, Fujino K, Jodai T, Sakata S, et al.
J Thorac Dis
. 2024 Mar;
16(2):1151-1160.
PMID: 38505064
Background: The clinical impact of tumor microvessels on the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in mutation-positive non-small cell lung cancer (NSCLC) is unclear. Thus, the aim...
6.
Shirakami C, Ikeda K, Hinokuma H, Nishi W, Shinchi Y, Matsubara E, et al.
Diagnostics (Basel)
. 2024 Mar;
14(5).
PMID: 38472943
In non-small cell lung cancer (NSCLC) cases, detecting potential lymph node metastases is essential to determine the indications for sublobar resection or adjuvant therapy. NUF2 is a tumor-specific antigen that...
7.
Katsumata S, Shimokawa M, Hamada A, Haratake N, Nomura K, Fujino K, et al.
Eur J Cancer
. 2024 Feb;
201:113951.
PMID: 38417299
Objectives: To clarify the impact of central nervous system (CNS) metastasis on performance status (PS) at relapse, on subsequent treatment(s), and on survival of patients with lung adenocarcinoma harboring common...
8.
Sanada M, Yamazaki M, Yamada T, Fujino K, Kudoh S, Tenjin Y, et al.
Hum Cell
. 2022 Dec;
36(1):409-420.
PMID: 36463543
The present study investigated the expression and role of ROR2 in small cell lung cancer (SCLC). To examine the expression of ROR2, 27 surgically resected SCLC tissue samples were immunostained...
9.
Akaike K, Saruwatari K, Matsushima R, Fujino K, Morinaga J, Oda S, et al.
J Thorac Dis
. 2022 Nov;
14(10):3801-3810.
PMID: 36389305
Background: Acute exacerbation of interstitial lung disease often causes fatal respiratory deterioration in lung cancer patients with interstitial lung disease. Here, we examined whether the maximum standardized uptake value of...
10.
Ishiwata T, Sage A, Fujino K, Mohammed N, Inage T, Bernards N, et al.
Chest
. 2022 Jul;
163(1):255-258.
PMID: 35841933
No abstract available.